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Summary  Despite  a  wide  choice  of  effective  antihypertensive  treatments,  blood  pressure
(BP) in  roughly  half  of  hypertensive  subjects  is  not  controlled.  Resistant  hypertension  is  deﬁned
as an  uncontrolled  BP  despite  optimal  doses  of  three  antihypertensive  treatments,  including  a
diuretic.  After  conﬁrmation  of  resistant  BP  using  home  BP  measurement  or  24-hour  ambulatorySympathetic  nervous
system;
Resistant
hypertension
BP monitoring  (ABPM),  patients  usually  go  through  a  work-up  to  rule  out  secondary  hyperten-
sion. If  secondary  hypertension  is  ruled  out,  the  recent  European  guidelines  on  hypertension
consider  baroreceptor  stimulation  or  renal  denervation  to  be  possible  options.  The  preva-
lence of  resistant  primary  hypertension  may  reach  up  to  10%  in  specialized  centres.  The  two
proposed non-pharmacological  therapeutic  strategies  have  been  developed  recently  to  inhibit
Abbreviations: ABPM, ambulatory blood pressure monitoring; BAT, baroreceptor activation therapy; BP, blood pressure; CT, computed
omography; DBP, diastolic blood pressure; LVEF, left ventricular ejection fraction; SBP, systolic blood pressure.
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sympathetic  overactivity  in  resistant  hypertension.  Among  them,  baroreceptor  activation  ther-
apy (BAT)  is  an  innovative  approach  that  interferes  with  baroreﬂex  function.  The  ﬁrst-generation
BAT device  (Rheos®;  CVRx,  Inc.,  Minneapolis,  MN,  USA)  demonstrated  good  efﬁcacy  in  lowering
ofﬁce BP  and  ABPM,  but  had  an  insufﬁcient  safety  proﬁle  due  to  complex  surgery.  The  second-
generation  BAT  device  (Barostim  neoTM system;  CVRx,  Inc.)  seems  to  share  the  same  BP-lowering
efﬁcacy but  has  a  better  safety  proﬁle.  We  report  the  ﬁrst  French  case  of  baroreceptor  stimu-
lation for  hypertension  using  the  Barostim  neoTM system.  We  also  discuss  the  pathophysiological
features  of  and  current  levels  of  evidence  for  this  technique.
© 2014  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé  Malgré  la  disponibilité  de  nombreuses  classes  d’anti-hypertenseurs,  la  moitié  des
patients hypertendus  ne  sont  pas  contrôlés.  L’hypertension  résistante  se  déﬁnit  par  une  pres-
sion artérielle  non  contrôlée  malgré  l’utilisation  de  trois  anti-hypertenseurs  à  doses  optimales
dont un  diurétique.  Après  conﬁrmation  par  auto-mesures  ou  holter  tensionnel,  les  patients
ayant une  hypertension  résistante  doivent  bénéﬁcier  d’un  bilan  complet  à  la  recherche  de
formes secondaires.  La  prévalence  de  l’hypertension  essentielle  résistante  est  de  l’ordre  de
5 à  10  %  dans  les  centres  spécialisés.  Les  recommandations  européennes  proposent  la  stimu-
lation des  barorécepteurs  ou  la  dénervation  rénale  en  cas  d’hypertension  non  contrôlées  par
les mesures  pharmacologiques.  Ces  deux  approches  non  pharmacologiques  ont  été  développées
récemment  pour  cibler  l’hyperactivation  du  système  nerveux  sympathique  dans  l’hypertension
artérielle résistante.  La  stimulation  des  barorécepteurs  carotidiens  est  une  approche  innovante
ciblant la  régulation  du  baro-réﬂexe.  La  première  génération  de  stimulateur  des  barorécep-
teurs (Rheos® ;  CVRx,  Inc.,  Minneapolis,  MN,  États-Unis)  a  démontré  une  bonne  efﬁcacité  en
termes de  baisse  de  pression  artérielle,  cependant  les  risques  opératoires  liés  à  la  complexité
de la  procédure  étaient  importants.  La  seconde  génération  de  stimulateur  des  barorécepteurs
(le système  Barostim  neoTM ;  CVRx,  Inc.)  semble  démontrer  une  efﬁcacité  similaire  en  termes
de baisse  de  pression  artérielle  et  un  meilleur  proﬁl  de  sécurité  en  raison  d’une  procédure
d’implantation  plus  simple.  Nous  présentons  le  premier  cas  franc¸ais  d’implantation  d’un  stim-
ulateur des  barorécepteurs  avec  le  système  Barostim  neoTM.  Nous  décrivons  également  les
aspects physiopathologiques  et  le  niveau  de  preuve  actuel  de  la  technique.
© 2014  Elsevier  Masson  SAS.  Tous  droits  réservés.
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Case reportBackground
Despite  a  wide  number  of  antihypertensive  treatments,
roughly  half  of  hypertensive  subjects  are  not  controlled
[1].  The  therapeutic  strategy  for  managing  resistant  hyper-
tension  has  been  simpliﬁed  recently  in  the  latest  French
guidelines  [2].  Resistant  hypertension  is  deﬁned  as  an  uncon-
trolled  blood  pressure  (BP)  despite  optimal  doses  of  three
antihypertensive  treatments,  including  a  diuretic.  Resistant
ofﬁce  BP  must  be  conﬁrmed  using  home  BP  measurement
or  24-hour  ambulatory  BP  monitoring  (ABPM).  When  resis-
tant  hypertension  is  conﬁrmed,  patients  undergo  a  work-up
to  rule  out  secondary  hypertension.  This  may  leave  up  to
10%  of  true  resistant  primary  hypertension  in  dedicated
centers  accustomed  to  the  management  of  hypertension
in  France  [3—5].  These  patients  may  be  considered  for
a  non-pharmacological  approach  (i.e.  renal  denervation).
While  this  technique  appeared  very  promising  after  the
SYMPLICITY  HTN-1  and  HTN-2  trials,  the  publication  of
the  SYMPLICITY  HTN-3  trial  has  cast  some  doubt  on  its
real  efﬁcacy  [6—8].  In  addition,  there  are  some  limitations
related  to  renal  function  (estimated  glomerular  ﬁltration
rate  <  45  mL/min)  and  renal  artery  anatomy  (length  and
diameter  before  bifurcation,  accessory  renal  arteries)  that
A
areclude  its  use  in  every  resistant  patient.  Thus,  there  is
till  room  for  other  approaches  in  this  currently  unsettled
eld.
One  alternative  (or  additional)  approach  could  be
aroreceptor  stimulation  —  a  novel  technique  targeting  the
aroreﬂex  via  stimulation  of  the  carotid  sinus  wall  [9].
he  recent  European  guidelines  on  hypertension  made  the
ollowing  recommendations:  to  consider  baroreceptor  stim-
lation  or  renal  denervation  in  case  of  ineffectiveness  of
rug  treatment  in  patients  with  resistant  hypertension  (class
Ib,  level  C)  and,  until  more  evidence  is  available  on  the
ong-term  efﬁcacy  and  safety  of  renal  denervation  and
aroreceptor  stimulation,  to  restrict  these  procedures  to
ypertension  centers  (class  I,  level  C)  [10].
We  report  here  on  the  ﬁrst  French  implantation  of  a
aroreceptor  stimulator  for  hypertension,  and  we  discuss
he  pathophysiological  features  of  and  current  levels  of  evi-
ence  for  this  technique. 74-year-old  man  was  referred  to  our  department  for  an
rterial  hypertension  work-up.  His  medical  history  included
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tigure 1. Implantation procedure. (A) Right carotid sinus exposu
he carotid sinus. (C) Decrease in blood pressure during activation 
eripheral  artery  disease  (bypass  graft  and  angioplasty),
ingle-vessel  coronary  artery  disease  treated  with  a  bare-
etal  stent  on  the  left  anterior  descending  artery,  with
 left  ventricular  ejection  fraction  (LVEF)  of  55%  and
bstructive  sleep  apnea  syndrome  treated  with  continuous
ositive  airways  pressure.  After  withdrawal  of  antihyper-
ensive  treatment  interfering  with  hormonal  status,  we
uled  out  secondary  endocrine  forms  of  hypertension  (mainly
rimary  aldosteronism,  Cushing’s  syndrome  and  pheochro-
ocytoma).  Duplex  ultrasound  did  not  demonstrate  any
igniﬁcant  renal  artery  stenosis.  Target  organ  damage
as  observed  at  the  level  of  the  heart  (left  ventricu-
ar  mass  index  155  g/m2),  vessels  (pulse  wave  velocity
6  m/s)  and  kidney  (estimated  glomerular  ﬁltration  rate
9  mL/min  and  microalbuminuria  280  mg/24  hours).  Antihy-
ertensive  treatment  was  gradually  optimized  and  a  low
ose  of  spironolactone  was  not  tolerated  because  of  hyper-
alemia.  Finally,  the  patient  received  daily:  indapamide
.5  mg,  amlodipine  10  mg,  valsartan  160  mg,  nebivolol  5  mg,
ilmenidine  1  mg  and  prazosin  5  mg.  ABPM  was  uncon-
rolled  on  supervised  intake  of  drugs:  172/75  mmHg,
4  hours;  172/76  mmHg,  daytime;  and  172/72  mmHg,  night-
ime  (non-dipper  status).  Long-term  non-compliance  with
ntihypertensive  treatment  was  unlikely  using  question-
aires  and  home  BP  measurement.  The  patient  was  ﬁrst
creened  for  renal  denervation.  A  computed  tomography
can  demonstrated  mild  atherosclerotic  stenosis  of  around
0%  on  both  renal  arteries  and  a  right  inferior  accessory  renal
rtery.  Moreover,  we  observed  an  occlusion  of  the  superﬁ-
ial  right  femoral  artery  and  an  occlusion  of  the  left  bypass.
enal  denervation  was  not  possible  because  of  two  exclusion
riteria:  renal  artery  atheroma  and  severe  peripheral  artery
isease.
Carotid  ultrasonography  ruled  out  signiﬁcant  atheroscle-
osis  (>  50%  reduction  in  diameter).  Baroreceptor  stimulator
mplantation  was  indicated.  Twenty-four  hours  before
2
a
f
C) Positioning of the electrode around the bifurcation in the area of
 generator.
urgery,  antihypertensive  treatments  that  interfere  with  the
ympathetic  nervous  system  were  withdrawn  (angiotensin
eceptor  blocker,  diuretics  and  beta-blockers)  and  replaced
ith  a  continuous  intravenous  infusion  of  nicardipine.  The
evel  of  the  right  carotid  bifurcation  was  marked  using
ltrasound  guidance.  General  analgesia  was  performed
ith  speciﬁc  drugs  (etomidate,  midazolam,  fentanyl  and
ocuronium)  known  for  their  limited  interaction  with  the
ympathetic  nervous  system.  A  catheter  was  placed  in  the
eft  radial  artery  for  continuous  BP  monitoring.  The  implan-
ation  procedure  consisted  of  a  right  carotid  sinus  exposure
ia  a  4  cm  incision  (Fig.  1A).  The  electrode  was  positioned
round  the  bifurcation  in  the  area  of  the  carotid  sinus
Fig.  1B).  The  electrode  and  lead  were  connected  to  the  bat-
ery  impulse  generator  and  brieﬂy  activated  with  impulses
f  3  V,  100  Hz  and  a  pulse  width  of  480  micros,  once  blood
ressure  and  heart  rhythm  were  stable.  The  hemodynamic
esponse  was  tested  and  the  electrode  was  repositioned  in
ifferent  locations  to  identify  the  site  of  optimal  response.
 marked  acute  reduction  in  BP  was  observed  from  171/64
o  119/45  mmHg  (Fig.  1C).  Once  the  optimal  location  was
onﬁrmed,  the  electrode  was  sutured  in  place;  then,  a  sub-
utaneous  pocket  was  made  inferior  to  the  right  clavicle
or  the  battery  impulse  generator  (Barostim  neoTM system;
VRx,  Inc.).  The  lead  was  advanced  under  the  skin  and  con-
ected  to  the  battery  (Fig.  2).  The  battery  impulse  generator
as  sutured  in  place  with  a  permanent  suture,  and  the
wo  incisions  were  closed  in  layers  with  absorbable  sutures.
ll  antihypertensive  treatments  were  started  24  hours  after
urgery,  and  the  patient  was  discharged  from  hospital  on  the
hird  day  after  device  implantation.
Baroreﬂex  activation  therapy  (BAT)  was  initiated  only
 weeks  after  implantation.  Programmed  variables  (pulse
mplitude,  pulse  width  and  frequency)  were  titrated
or  optimal  response  over  the  ﬁrst  few  months.  Trained
VRx  ﬁeld  staff  performed  device  programming  under  the
Baroreceptor  stimulation  for  resistant  hypertension  693
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1Figure 2. Implantation procedure: subcutaneous pocket for the b
direction  of  the  clinician.  Prazosin  was  withdrawn  after
initiation  of  the  therapy  because  of  orthostatic  hypotension.
BAT  was  well  tolerated,  with  only  a  transient  episode  of
cough  and  hoarseness  when  a  high  intensity  of  stimulation
was  used.  After  9  months  of  follow-up,  we  observed  a  reduc-
tion  of  15  mmHg  in  SBP  and  a  reduction  of  8  mmHg  in  DBP
on  24-hour  ABPM  (157/67  mmHg,  24  hours;  158/67  mmHg,
daytime;  and  155/66  mmHg,  night-time),  with  ﬁve  anti-
hypertensive  drugs:  indapamide  1.5  mg;  amlodipine
10  mg;  valsartan  160  mg;  nebivolol  5  mg;  and  rilmenidine
1  mg.
Pathophysiological effects of sympathetic
activity in hypertension
Different  mechanisms  are  involved  in  the  pathogenesis  of
hypertension  and  particularly  in  resistant  hypertension:  the
renin-angiotensin-aldosterone  system,  the  kidneys,  and  the
sympathetic  nervous  system.  Sympathetic  overactivity  has
been  associated  with  increased  BP  and  also  with  a  high  inci-
dence  of  target  organ  damage:  left  ventricular  hypertrophy,
renal  failure,  and  hypertensive  retinopathy  [11,12].  Pharma-
cological  agents  (beta-blockers,  alpha-blockers,  centrally
acting  drugs)  and,  more  recently,  non-pharmacological
therapeutics  (renal  denervation,  baroreceptor  stimulation)
have  been  developed  to  inhibit  sympathetic  overactivity  in
hypertension  (Fig.  3).  Baroreﬂex  regulation  originates  from
baroreceptors  located  in  the  aortic  arch  and  carotid  sinuses.
Baroreceptors  are  mechanoreceptors  that  are  activated  by
pressure-induced  stretch  on  the  vessel  wall.  Baroreceptor
afferents  from  the  carotid  sinus  travel  in  the  carotid  sinus
nerve  before  joining  the  glossopharyngeal  nerve  (IX),  while
those  from  the  aortic  arch  travel  in  the  vagus  nerve  (X).
All  baroreceptor  afferents  terminate  in  the  nucleus  of  the
tractus  solitarius  in  the  medulla  of  the  brain.  Efferents  of
the  central  nervous  system  are  represented  by  sympathetic
ﬁbres  for  the  heart  and  vessels,  but  also  by  parasympathetic
ﬁbres  only  for  the  heart.  The  sympathetic  and  parasym-
pathetic  tones  allow  tight  control  of  BP  in  the  short-term
(Fig.  4).
Alteration  of  the  baroreﬂex  is  a  common  phenomenon
in  chronic  hypertension.  Indeed,  a  sustained  BP  elevation
implies  a  diminished  baroreceptor  response;  this  is  known
as  baroreﬂex  resetting  and  corresponds  to  a  new  threshold
of  baroreceptor  activation  [13].  Baroreceptor  stimulation
seems  to  be  an  innovative  approach  to  restore  this  patho-
physiological  feature  in  hypertensive  subjects.
f
i
e
hry impulse generator and tunnel for connecting the lead.
urrent level of evidence for
aroreceptor stimulation
esistant hypertension
he  original  implantable  active  medical  BAT  device  (Rheos®;
VRx,  Inc.,  Minneapolis,  MN,  USA)  activates  the  carotid
aroreﬂex  through  electrical  stimulation  of  the  walls  of  both
arotid  sinuses  (Fig.  5).  Both  electrodes  implanted  on  the
xterior  surface  of  the  carotid  sinus  wall  are  connected  to
 battery-powered  impulse  generator.  This  concept  was  ini-
ially  validated  in  animal  studies.  In  conscious  dogs,  7  days
f  baroreﬂex  activation  demonstrated  a  sustained  reduc-
ion  in  heart  rate,  mean  arterial  BP  and  norepinephrine
oncentration  [14].  In  the  same  animal  model,  a high  contin-
ous  infusion  of  angiotensin  II  was  associated  with  a  lower
ffect  of  baroreﬂex  activation  on  BP  [15].  In  a  dog  model
f  obesity-induced  hypertension  with  a  fatty  diet,  the  same
eam  observed  that  baroreﬂex  activation  chronically  sup-
ressed  the  sympathoexcitation  associated  with  obesity  and
bolished  the  attendant  hypertension  [16].
The  ﬁrst-in-man  feasibility  of  BAT  was  described  in  2007
n  17  patients  with  drug-resistant  hypertension  (5.2  ±  1.8
ntihypertensive  drugs)  enrolled  in  a European  multicen-
re  study  [9]. These  preliminary  data  suggested  that  the
rocedure  had  an  acceptable  safety  level,  with  a  low  rate
f  adverse  events:  one  hypoglossal  nerve  injury  (symptoms
f  hoarseness  and  eating  disturbances),  which  improved
uring  follow-up,  and  one  infection  requiring  complete
emoval  of  the  device.  Overall,  ofﬁce  blood  BP  fell  by
8/16  mmHg.  Three  years  later,  Device  Based  Therapy  in
ypertension  Trial  (DEBuT-HT)  —  a  multicentre  prospective
on-randomized  feasibility  study  to  assess  the  safety  and
fﬁcacy  of  the  Rheos® system  over  3  months  —  was  published
17]. Forty-ﬁve  patients  with  systolic  BP  (SBP)  ≥  160  mmHg
r  diastolic  BP  (DBP)  ≥  90  mmHg  despite  at  least  three
ntihypertensive  drugs  were  enrolled,  and  were  followed
p  for  as  long  as  2  years.  After  3  months  of  BAT,  the
ean  ofﬁce  BP  was  reduced  by  21/12  mmHg  (P  <  0.001)
nd  ABPM  was  reduced  by  6/4  mmHg  (P  =  0.102).  After  1
nd  2  years  of  follow-up,  the  ofﬁce  BP  fell  by  30/20  mmHg
nd  33/22  mmHg  respectively  (P  <  0.002  for  both).  The
ame  trend  was  observed  with  ABPM,  which  decreased  by
3/8  mmHg  at  1  year  and  24/13  mmHg  at  2  years  (P  <  0.05
or  all).  Some  serious  adverse  events  were  reported:  three
nfections  requiring  the  device  to  be  explanted;  one  periop-
rative  stroke,  probably  due  to  intraoperative  injury  to  the
ypoglossal  nerve  (tongue  paresis  without  abnormalities  on
694  P.-Y.  Courand  et  al.
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Aigure 3. Therapeutic targets of the sympathetic nervous system
rain  magnetic  resonance  imaging);  and  one  movement  of
he  implantable  pulse  generator,  resulting  in  the  need  for
urther  surgery  to  reposition  the  implantable  pulse  genera-
or.
In  2012,  a  double-blind  randomized  trial  of  265  subjects
ith  resistant  hypertension  was  performed  [18].  All  patients
ere  implanted  and  subsequently  randomized  (2:1)  either  to
roup  A  with  BAT  for  the  ﬁrst  6  months  or  to  group  B  with
elayed  BAT  initiation  following  the  6-month  visit.  The  trial
howed  signiﬁcant  beneﬁts  for  three  of  the  ﬁve  co-primary
ndpoints:  sustained  efﬁcacy  (reduction  in  SBP  of  at  least
0  mmHg  at  12  months,  88%  responders),  BAT  safety  (40%
ate  of  reduction  in  hypertensive  events  in  Group  A),  and
evice  safety  (2.3%  hypertension-related  stroke).  The  two
ther  co-primary  endpoints  did  not  show  signiﬁcant  beneﬁt:
cute  SBP  responders  at  6  months  (achievement  of  10  mmHg
all  in  SBP  compared  with  month  0,  Group  A  54%,  Group  B
6%;  P  =  0.97);  and  procedure  safety  (4.4%  transient  nerve
njury,  4.8%  permanent  nerve  injury,  4.8%  general  surgical
omplications  and  2.8%  respiratory  complaint).  The  authors
oncluded  that  signiﬁcant  and  sustained  reductions  in  SBP
ere  observed,  but  that  new  technology  for  delivering  BAT,
hich  involves  a  less  invasive  implantation  procedure,  was
eeded.  Long-term  follow-up  of  22—53  months  conﬁrmed
he  maintenance  of  the  BP  reduction  [13].
A  second-generation  system  for  delivering  BAT  (Barostim
eoTM system;  CVRx,  Inc.,  Minneapolis,  MN,  USA)  (Fig.  5),
ith  a  simpler  device  and  implantation  procedure,  has
d
o
w
typertension.
een  evaluated  in  a  single-arm  open-label  study  [19].  The
lectrode  portion  of  the  lead  consists  of  a single  platinum-
ridium  disc  coated  with  iridium  oxide  and  attached
oncentrically  to  a  circular  insulative  backer  that  is  directly
utured  to  the  carotid  sinus.  The  miniaturized  electrode
nd  unilateral  system  design  facilitate  a  minimally  inva-
ive  implantation  procedure.  Thirty  patients  with  resistant
ypertension  were  enrolled.  With  stable  antihypertensive
reatment,  ofﬁce  BP  fell  by  26/12  mmHg  at  6  months  and
he  safety  proﬁle  was  similar  to  that  for  a  pacemaker.  Dur-
ng  the  perioperative  period  of  30  days  after  surgery,  three
omplications  occurred:  a  self-inﬂicted  wound  complica-
ion;  a  pulse  generator  pocket  hematoma;  and  discomfort  in
he  pulse  generator  pocket,  requiring  device  repositioning.
 major  limitation  of  this  study  was  the  absence  of  ABPM.
Thus,  in  resistant  hypertension,  BAT  seems  an  option,
lthough  the  only  randomized  study  did  not  reach  its  efﬁcacy
ndpoint;  no  comparable  study  with  the  second-generation
evice  is  currently  available.  Many  more  data  with  this  tech-
ique  are  thus  required  to  validate  its  use.  In addition,  some
hysiological  features  are  far  from  being  understood,  includ-
ng  the  fact  that  the  BP  response  can  be  sustained  while  the
aroreﬂex  is  mainly  involved  in  short-term  BP  regulation.
nother  feature  relates  to  the  apparent  lack  of  baroreceptor
ownregulation  —  a  common  phenomenon  observed  in  case
f  chronic  stimulation  [20]. This  new  technique  opens  the
ay  for  future  research.  Concerning  clinical  aspects,  a  mul-
icentre  French  randomized  trial  is  about  to  start;  it  will
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Figure 4. Regulation of blood pressure via the baroreﬂex.
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underway.  Patients  were  included  with  an  LVEF  <  35%  and  aFigure 5. First-generation and second-generation baroreceptor
stimulators.
evaluate  the  Barostim  neoTM system  compared  with  medi-
cal  treatment  alone,  with  special  attention  paid  to  safety,
beneﬁt  on  ABPM  and  cost-effectiveness.
Perspectives
Baroreceptor  stimulation  and  renal  denervation  are  new
ways  of  treating  hypertension.  While  these  techniques  are
extremely  appealing,  one  has  to  recognize  that  their  real
effects  on  BP  —  and,  even  more,  on  adverse  cardiovascular
N
h
rvents  —  are  unknown.  Sticking  to  the  BP  effect,  the  results
f  SYMPLICITY  HTN-3  trial  on  renal  denervation  have  been
ather  disappointing  compared  with  previous  SYMPLICITY  tri-
ls  [6—8,21].  The  major  information  from  this  trial  is  the
lacebo  effect  of  this  therapy,  which  was  neglected  in  early
rials;  this  has  to  be  taken  into  account  in  the  same  way  as
or  any  medical  treatment.  Extensive  use  of  ABPM,  which
s  less  affected  by  the  placebo  effect  than  conventional  BP
easurement,  is  highly  desirable  to  assess  the  real  effect  of
hese  techniques.  Another  limitation  is  adherence  to  treat-
ent;  an  advantage  of  the  French  DENER  HTN  study  is  that
t  monitored  this  factor  precisely.  Obviously,  when  design-
ng  future  trials  on  the  Barostim  neoTM system,  these  two
actors  should  be  carefully  considered.
ther potential cardiovascular applications
eart  failure  could  be  another  application  for  BAT.  Chronic
AT  has  demonstrated  enhancement  of  survival  in  dogs
ith  rapid  pacing-induced  heart  failure  [22].  In  dogs
ith  coronary  microembolization-induced  heart  failure,  BAT
emonstrated  an  increase  in  LVEF  and  a  partial  reversal  of  LV
emodeling  compared  with  a  control  group  [23]. A  random-
zed  heart  failure  study  involving  140  subjects  is  currentlyew  York  Heart  Association  Class  III  under  optimal  stable
eart  failure  therapy  for  at  least  4  weeks,  including  cardiac
esynchronization  therapy  if  indicated.
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The  effect  of  BAT  on  arrhythmias  can  be  speculated  upon,
iven  the  major  effect  of  beta-blockers.  Further  application
eeds  to  be  tested  in  this  setting,  such  as  severe  ventricular
rrhythmia  despite  optimal  treatment.
onclusion
AT  is  an  innovative  approach  for  treating  resistant
ypertension  via  modulation  of  the  baroreﬂex.  The  ﬁrst-
eneration  BAT  device  (Rheos®)  showed  some  effect  on
P  in  resistant  hypertension,  but  its  safety  proﬁle  was
ot  satisfactory  due  to  the  complexity  of  the  surgery.
he  second-generation  BAT  device  (Barostim  neoTM system),
lthough  it  only  applies  stimulation  to  one  carotid,  has  sim-
lar  efﬁcacy  in  terms  of  BP-lowering,  with  a  good  safety
roﬁle,  offering  interesting  perspectives.  Further  study  is
eeded  to  evaluate  this  latest  device,  and  a  French  ran-
omized  trial  will  soon  be  launched.
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